Bluebird Bio
(NQ:
BLUE
)
0.5289
-0.0398 (-7.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM
December 12, 2021
From
bluebird bio, Inc.
Via
Business Wire
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
December 12, 2021
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...
Via
Benzinga
Exposures
Product Safety
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
December 11, 2021
From
bluebird bio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 22, 2021
Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 22, 2021
Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday!
Via
InvestorPlace
Exposures
Product Safety
Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA
November 22, 2021
The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has...
Via
Benzinga
Exposures
Product Safety
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
November 22, 2021
From
bluebird bio, Inc.
Via
Business Wire
64 Biggest Movers From Yesterday
November 09, 2021
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile...
Via
Benzinga
Why Bluebird Bio Stock Plunged Today
November 08, 2021
Two analysts downgraded the biotech stock.
Via
The Motley Fool
Market Rally Continues as Dow Nabs Intraday Highs
November 08, 2021
S&P 500 Index and Nasdaq Composite are sporting modest gains, with the Dow locking in another fresh intraday high.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
38 Stocks Moving In Monday's Mid-Day Session
November 08, 2021
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares climbed 129.8% to $7.49 after the company announced the launch of its E-Boost portfolio of mobile Electric Vehicle...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 08, 2021
Gainers PetVivo Holdings (NASDAQ:PETV) s...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
November 08, 2021
Upgrades For Nektar Therapeutics (NASDAQ:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 05, 2021
Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1....
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 05, 2021
Gainers Ontrak (NASDAQ:OTRK) shares rose 21.82% to $11.78 during Friday's pre-market session. The market value of their outstanding shares is at $225.5 million. As per...
Via
Benzinga
92 Biggest Movers From Friday
November 08, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...
Via
Benzinga
64 Stocks Moving In Friday's Mid-Day Session
November 05, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the...
Via
Benzinga
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
November 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
November 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
28 Stocks Moving in Friday's Pre-Market Session
November 05, 2021
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 65.8% to $2.14 in pre-market trading after the company announced its ReBoot device has been granted designation as a Breakthrough...
Via
Benzinga
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
November 04, 2021
From
bluebird bio, Inc
Via
Business Wire
bluebird bio Completes Planned Business Separation
November 04, 2021
From
bluebird bio, Inc.
Via
Business Wire
Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe
October 21, 2021
Bluebird Bio Inc (NASDAQ: BLUE) will withdraw the regulatory marketing authorization for Skysona (elivaldogene autotemcel) in the European Union. The update comes...
Via
Benzinga
Could This Beaten-Down Biotech Stock Be the Next Buyout Target?
October 20, 2021
This gene-therapy specialist may need some help turning things around.
Via
The Motley Fool
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
October 18, 2021
From
bluebird bio, Inc.
Via
Business Wire
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
October 11, 2021
These once-promising biotech stocks are trading at a fraction of their all-time highs right now.
Via
The Motley Fool
bluebird bio Provides Update on Upcoming Planned Business Separation
October 08, 2021
From
bluebird bio, Inc.
Via
Business Wire
Bluebird Bio Files US Application For β-thalassemia Gene Therapy
September 22, 2021
Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel)...
Via
Benzinga
Exposures
Product Safety
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
September 21, 2021
From
bluebird bio, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.